The Skin and Natural Cannabinoids-Topical and Transdermal Applications

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2023 Jul 29

PMID 37513960

Authors

Silviu-Iulian Filipiuc

Anca-Narcisa Neagu

Cristina Mariana Uritu

Bogdan-Ionel Tamba

Leontina-Elena Filipiuc

Ivona Maria Tudorancea

Andreea Nicoleta Boca

Madalina Florina Hancu

Vlad Porumb

Walther Bild

Affiliations

Soon will be listed here.

Abstract

The chemical constituents of the plant known as cannabinoids have been extensively researched for their potential therapeutic benefits. The use of cannabinoids applied to the skin as a potential method for both skin-related benefits and systemic administration has attracted increasing interest in recent years. This review aims to present an overview of the most recent scientific research on cannabinoids used topically, including their potential advantages for treating a number of skin conditions like psoriasis, atopic dermatitis, and acne. Additionally, with a focus on the pharmacokinetics and security of this route of administration, we investigate the potential of the transdermal delivery of cannabinoids as a method of systemic administration. The review also discusses the restrictions and difficulties related to the application of cannabinoids on the skin, emphasizing the potential of topical cannabinoids as a promising route for both localized and systemic administration. More studies are required to fully comprehend the efficacy and safety of cannabinoids in various settings.

Citing Articles

Efficacy and Safety of Transdermal Medical Cannabis (THC:CBD:CBN formula) to Treat Painful Diabetic Peripheral Neuropathy of Lower Extremities.

Seevathee K, Kessomboon P, Manimmanakorn N, Luangphimai S, Thaneerat T, Wanaratna K Med Cannabis Cannabinoids. 2024; 8(1):1-14.

PMID: 39720705 PMC: 11666268. DOI: 10.1159/000542511.

Exploring the Biological Activity of Phytocannabinoid Formulations for Skin Health Care: A Special Focus on Molecular Pathways.

Trigo G, Coelho M, Ferreira C, Melosini M, Lehmann I, Reis C Int J Mol Sci. 2024; 25(23).

PMID: 39684852 PMC: 11641943. DOI: 10.3390/ijms252313142.

Exploring Endocannabinoid System: Unveiling New Roles in Modulating ER Stress.

Capolupo I, Miranda M, Musella S, Di Sarno V, Manfra M, Ostacolo C Antioxidants (Basel). 2024; 13(11).

PMID: 39594426 PMC: 11591047. DOI: 10.3390/antiox13111284.

Cannabinoids in Integumentary Wound Care: A Systematic Review of Emerging Preclinical and Clinical Evidence.

Niyangoda D, Muayad M, Tesfaye W, Bushell M, Ahmad D, Samarawickrema I Pharmaceutics. 2024; 16(8).

PMID: 39204426 PMC: 11359183. DOI: 10.3390/pharmaceutics16081081.

JWH-182: a safe and effective synthetic cannabinoid for chemotherapy-induced neuropathic pain in preclinical models.

Filipiuc L, Creanga-Murariu I, Tamba B, Ababei D, Rusu R, Stanciu G Sci Rep. 2024; 14(1):16242.

PMID: 39004628 PMC: 11247095. DOI: 10.1038/s41598-024-67154-y.

References

Eberlein B, Eicke C, Reinhardt H, Ring J . Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2008; 22(1):73-82. DOI: 10.1111/j.1468-3083.2007.02351.x. View

Richard M, Paul C, Nijsten T, Gisondi P, Salavastru C, Taieb C . Prevalence of most common skin diseases in Europe: a population-based study. J Eur Acad Dermatol Venereol. 2022; 36(7):1088-1096. PMC: 9415115. DOI: 10.1111/jdv.18050. View

Norooznezhad A, Norooznezhad F . Cannabinoids: Possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation. Med Hypotheses. 2017; 99:15-18. DOI: 10.1016/j.mehy.2016.12.003. View

Johal H, Vannabouathong C, Chang Y, Zhu M, Bhandari M . Medical cannabis for orthopaedic patients with chronic musculoskeletal pain: does evidence support its use?. Ther Adv Musculoskelet Dis. 2020; 12:1759720X20937968. PMC: 7333482. DOI: 10.1177/1759720X20937968. View

Huestis M . Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol. 2006; (168):657-90. DOI: 10.1007/3-540-26573-2_23. View

Shao K, Stewart C, Grant-Kels J . Cannabis and the skin. Clin Dermatol. 2021; 39(5):784-795. DOI: 10.1016/j.clindermatol.2021.05.006. View

Gloss D . An Overview of Products and Bias in Research. Neurotherapeutics. 2015; 12(4):731-4. PMC: 4604179. DOI: 10.1007/s13311-015-0370-x. View

Landis E, Davis S, Feldman S, Taylor S . Complementary and alternative medicine use in dermatology in the United States. J Altern Complement Med. 2014; 20(5):392-8. PMC: 4011482. DOI: 10.1089/acm.2013.0327. View

Zuardi A . History of cannabis as a medicine: a review. Braz J Psychiatry. 2006; 28(2):153-7. DOI: 10.1590/s1516-44462006000200015. View

10.

Stella B, Baratta F, Pepa C, Arpicco S, Gastaldi D, Dosio F . Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain. Drugs. 2021; 81(13):1513-1557. PMC: 8417625. DOI: 10.1007/s40265-021-01579-x. View

11.

Zhao Z, Guan D, Liu W, Wang T, Fan Y, Cheng Z . [Expression of cannabinoid receptor I during mice skin incised wound healing course]. Fa Yi Xue Za Zhi. 2010; 26(4):241-5. View

12.

Fang J, Fang C, Liu C, Su Y . Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2008; 70(2):633-40. DOI: 10.1016/j.ejpb.2008.05.008. View

13.

Nickles M, A Lio P . Cannabinoids in Dermatology: Hope or Hype?. Cannabis Cannabinoid Res. 2020; 5(4):279-282. PMC: 7759267. DOI: 10.1089/can.2019.0097. View

14.

Eichler M, Spinedi L, Unfer-Grauwiler S, Bodmer M, Surber C, Luedi M . Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. Planta Med. 2012; 78(7):686-91. DOI: 10.1055/s-0031-1298334. View

15.

Kendall A, Pilkington S, Massey K, Sassano G, Rhodes L, Nicolaou A . Distribution of bioactive lipid mediators in human skin. J Invest Dermatol. 2015; 135(6):1510-1520. DOI: 10.1038/jid.2015.41. View

16.

McPartland J . Systematics at the Levels of Family, Genus, and Species. Cannabis Cannabinoid Res. 2018; 3(1):203-212. PMC: 6225593. DOI: 10.1089/can.2018.0039. View

17.

Schrader N, Gorell E, Stewart R, Duipmans J, Harris N, Perez V . Cannabinoid use and effects in patients with epidermolysis bullosa: an international cross-sectional survey study. Orphanet J Rare Dis. 2021; 16(1):377. PMC: 8419930. DOI: 10.1186/s13023-021-02010-0. View

18.

Chen X, Zhu L, Li R, Pang L, Zhu S, Ma J . Electroporation-enhanced transdermal drug delivery: Effects of logP, pK, solubility and penetration time. Eur J Pharm Sci. 2020; 151:105410. DOI: 10.1016/j.ejps.2020.105410. View

19.

Paudel K, Hammell D, Agu R, Valiveti S, Stinchcomb A . Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Dev Ind Pharm. 2010; 36(9):1088-97. DOI: 10.3109/03639041003657295. View

20.

Tortolani D, Di Meo C, Standoli S, Ciaramellano F, Kadhim S, Hsu E . Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway. Int J Mol Sci. 2023; 24(3). PMC: 9917187. DOI: 10.3390/ijms24032721. View